Botulinum Toxin Market To Reach USD 6.51 Billion By 2030 Growing At A CAGR Of 7.53% During 2022 – 2030

According to the most recent analysis by Emergen Research, the global market for botulinum toxin reached USD 3.40 billion in 2021 and is projected to grow at a revenue CAGR of 7.53% during the following five years. Increasing prevalence of chronic migraine and limb stiffness, as well as an increase in the number of elderly and middle-aged patients receiving botulinum toxin operations, are anticipated to propel market revenue growth during the forecast period.

The bacteria Clostridium botulinum produces the protein and neurotoxin known as botulinum toxin. When injected into the muscle, the toxin, which is a specific blocker of acetylcholine released from nerves, prevents neural transmission from the nerves. One of the most extraordinary chemicals discovered in science and medicine is botulinum toxin. Over the past ten years, the use of botulinum toxin in cosmetology has expanded quickly, and it is currently one of the most popular and commonly used aesthetic procedures worldwide. The number of cosmetic treatments has increased as a result of rising concerns about aesthetic qualities in both developed and developing countries.

The market will increase more quickly as more botulinum toxin medicines, including Botox, Xeomin, and disport, become available. Over the future years, the market growth is anticipated to be boosted by the rising use of botulinum toxin injection in a number of aesthetic operations, such as the treatment of glabellar lines, chemical browlifts, and forehead lines. There are now only a few Type-A botulinum toxin products on the market, and only one Type-B product (Myobloc). Although there are increasing chances for the extension of botulinum toxin’s therapeutic application area in the near future, major producers are increasing their investment in R&D operations to investigate the therapeutic use of the toxin.

Some Key Highlights From the Report :

With a revenue share of more than 50.0% in 2021, the therapeutic category dominated the market. The most potent biological neurotoxic molecule known is known as botulinum toxin, and it shows significant promise for the treatment of numerous illnesses. Due to a greater understanding of the various modes of action and molecular behaviour of the botulinum toxin, the therapeutic benefits of this substance have been expanding. Botox operations are used for a variety of therapeutic and preventive therapies for illnesses like hyperhidrosis, chronic migraines, and overactive bladders. The market is divided into aesthetic and therapeutic uses based on application.

In 2021, the segment for hospitals had the highest revenue share—more than 50.0%. The expansion of this market is being aided by an increase in hospitals offering cutting-edge medical treatment and amenities in both developed and emerging nations, as well as by growing public awareness of aesthetic operations. Additionally, the majority of therapeutic operations for conditions including dystonia, spasticity, and chronic migraines are carried out in hospitals. The market is divided into hospitals, dermatological clinics, spas, and cosmetic surgery centres based on end-use.

A gram-positive anaerobic bacterium called Clostridium botulinum produces the neurotoxic protein known as botulinum toxin. The neurotransmitter acetylcholine cannot be released from axons that terminate at the neuromuscular junction due to botulinum toxin. This non-invasive cosmetic process is used, among other things, to minimise crow’s feet, forehead creases, and fine lines on the face.

The COVID-19 pandemic’s introduction has had a negative effect on the world market. Due to the rising number of COVID-19 cases in 2020, numerous non-emergency surgical and therapeutic treatments as well as non-invasive procedures were postponed. These operations are classified as optional surgeries and aren’t thought of as crucial, life-saving operations.

Due to the growing popularity of cosmetic botulinum toxin-based solutions for the temporary elimination of forehead lines, wrinkles, and glabellar lines that are commercially available, the facial wrinkles category is anticipated to account for the biggest revenue share between 2022 and 2030. Another element fueling the segment’s sales growth is the aged and geriatric population’s growing preference for cosmetics to improve look.

Some major companies profiled in the global market report include AbbVie Inc., Galderma S.A., Merz Pharma GmbH & Co. KGaA, Ipsen Pharma, Medy Tox Inc., Revance Therapeutics Inc., HUGEL, Inc., Daewoong Pharmaceutical Co., Ltd., Clarion Medical Technologies, Elan Pharmaceuticals, Inc.

Emergen Research has segmented the global botulinum toxin market on the basis of media, cell line, application, end-use, and region:

  • Type Outlook (Revenue, USD Billion, 2019–2030)
    • Botulinum Toxin A
      1. OnabotulinumtoxinA
      2. AbobotulinumtoxinA
      3. IncobotulinumtoxinA
      4. PrabotulinumtoxinA
    • Botulinum Toxin B
  • Application Outlook (Revenue, USD Billion, 2019–2030)
    • Muscle Spasticity
    • Migraine
    • Facial Wrinkles
    • Focal Dystonias
    • Hyperhidrosis
    • Chronic Pain
    • Others
  • End-Use Outlook (Revenue, USD Billion, 2019–2030)
    • Medical Spas & Beauty Centers
    • Hospitals
    • Dermatology Clinics
    • Others

To get leading market solutions, visit the link below: visit Here